RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #RNA
Alnylam Pharmaceuticals
Biotechnology Research
Cambridge, Massachusetts 203,928 followers
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
Über uns
ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-23), Science Magazine (2018-23), Fast Company (Best Workplaces for Innovators 2020-23) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861
- Website
-
http://www.alnylam.com
External link for Alnylam Pharmaceuticals
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 1.001-5.000 Mitarbeiter
- Hauptsitz
- Cambridge, Massachusetts
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2002
- Spezialitäten
- Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, and RNAi
Standorte
Employees at Alnylam Pharmaceuticals
Aktualisierungen
-
Healthcare Professionals: Characterized by severe, diffuse abdominal pain and a range of other seemingly unrelated symptoms, acute hepatic #porphyria (AHP) can be misleading and is often misdiagnosed. Learn what to look for to better detect this #RareDisease: https://bit.ly/3mpod2h
-
Managing a #RareDisease like primary #hyperoxaluria type 1 (PH1) can be difficult, so it can be helpful to work with patient advocacy groups and community members to answer questions and get more information. Hear from Kim Hollander of the Oxalosis and Hyperoxaluria Foundation in an episode of Medical Stories airing on PBS stations. https://bit.ly/3ATSDVR
-
Healthcare Professionals: Do you have a patient presenting with severe, diffuse abdominal pain and seemingly unrelated symptoms? It could be acute hepatic #porphyria (AHP). Random (spot) urine tests are the primary method to help diagnose AHP and a genetic test can determine the type. Learn more about testing for AHP: https://bit.ly/2RCBrKF
-
Unlocking the full potential of #RNAiTherapeutics, ensuring that patients at the center of all we do and delivering value to healthcare stakeholders are what drive us to innovate. Our Chief Commercial Officer Tolga Tanguler discusses our approach to patient access in this article where you can also view our latest Patient Access Philosophy Report: https://bit.ly/3WdnzsO #PatientAccess #RNAi #RNAinterference #biotech #biopharma
-
We're honored to be a #Humankind100 Top 100 company for the 3rd year in a row! The commitment to having a positive impact through the innovative medicines we make and extensive community engagement, while operating ethically and transparently, is deeply personal for our employees and is engrained in every aspect of our business. Learn more about this recognition from Humankind Investments: https://bit.ly/3M7zGRV #CorporateResponsibility #ESG #Sustainability
-
Alnylam Pharmaceuticals reposted this
The sheer scale of people who continue to be displaced due to economic, social, and military conflicts is shocking. Through our Alnylam Challengers social impact program, we support organizations in Spain, the UK, the Netherlands, and Italy, providing critical services to #refugees so they can rebuild their lives with dignity. I recently visited with our Alnylam Challengers partners Refugee Action, Forward·Inc and Soleterre to hear more about the successes, challenges, and ongoing needs in each country. They described the critical work they do to help refugees prepare for careers in their new homes, from amplifying digital skills to providing language support and much more. They also highlighted how grateful they are for our employees who serve as volunteer mentors and help raise charitable donations to bolster their work. Thanks to my colleagues Marco Fossatelli Fiona McMillan Federica Stucchi Philip Davey Domenico Guajana Christine Regan Lindenboom Brendon Pires Samip Dhakal Seth Levine Sergio Bullón Marta Calomarde for their leadership and support. To learn more about our Challengers program, read this article written by Phil Davey, Alnyalm Country Manager for the UK & Ireland, and Tim Naor Hilton, Chief Executive, Refugee Action - https://lnkd.in/eRHb4nUf
-
As a pioneer in RNA-based therapeutics, we relish the opportunity to engage with peers and discuss what's new and next in nucleic acid medicines. If you do too, join us and co-organizers Nature Biotechnology, Ionis Pharmaceuticals, Inc. and UC San Diego School of Medicine at the #RNAbench2bedside conference happening Dec 9-11. Learn more: https://lnkd.in/e5DmnhGA and submit an abstract through Oct 9: https://bit.ly/3WJddzQ #RNA #RNAi #RNAinterference #RNAiTherapeutics #siRNA
-
We’re harnessing the potential of RNA interference (RNAi) and will be presenting new data at the European Society of Cardiology Congress 2024 8/30-9/2 in London. Learn more: https://bit.ly/3X4wxZL
Ähnliche Seiten
Jobs durchsuchen
Aktie
ALNY
NASDAQ
20 Minuten Verzögerung
$251.48
-1.66 (-0.656%)
- Öffnen Sie
- 251.86
- Niedrig
- 249.95
- Hoch
- 255.24
Daten von Refinitiv
Siehe mehr Informationen auf